This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The approval of Niktimvo in graft-versus-host disease hands Incyte another immune system-regulating medicine that analysts see as valuable, especially if use is broadened through additional clearances.
Livdelzi, which Gilead inherited through its acquisition of CymaBay, will now compete with medicines for primary biliary cholangitis that are currently marketed by Ipsen and Alfasigma.
Livdelzi, which Gilead inherited through its acquisition of CymaBay, will now compete with medicines for primary biliary cholangitis that are currently marketed by Ipsen and Alfasigma.
AI's role in inventing new drugs raises questions about ownership rights in the pharmaceutical sector. Explore the complexities of defining ownership in drug discovery with AI technology.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Katarina Wikstrom has worked for over 20 years in the field of translational molecular oncology and holds the position of VP global product development at Almac Diagnostic Services.
Tonix Pharmaceuticals has announced promising phase 3 trial results for TNX-102 SL (sublingual cyclobenzaprine HCl), a treatment targeting fibromyalgia.
The Chronic Pain and Fatigue Research Center at the University of Michigan is requesting applications for the HEAL National K12 Clinical Pain Career Development Award (HEAL K12). The HEAL K12 is a mentored career development program designed to provide protected time for clinicians and scientists to focus on training in and conducting clinical pain research.
Just as a new strain of mpox spreads across Africa, results from a preliminary analysis of a study that began during the 2022 viral outbreak stands to provide more clarity on the clinical benefit o | Despite missing the trial's primary endpoint of time to lesion resolution, the study suggested that the treatment may be most beneficial for those treated early and those with severe disease.
Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, Oregon.
Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the | Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the original lawsuit.
So far in August, the FDA has announced two separate drug recalls on its website: one related to particulate concerns and the other thanks to high endotoxin levels. | So far in August, the FDA has announced two separate drug recalls on its website: one related to particulate concerns and the other thanks to high endotoxin levels. While neither recall has resulted in any safety flags or side effect reports so far, the issues stemming from the faulty products could be severe, the drugmakers have w
The clinical operations and trial management community is buzzing with anticipation as the most influential leaders in the field prepare to convene at the
Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to unite, pending approval, into a single entity that will merge Recursion's biological proficiency with Exscientia's chemical specialisation.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gi | In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.
In the ever-evolving landscape of healthcare marketing, understanding audience engagement and measuring success is paramount. In a recent PM360 Think Tank article , Iyiola Obayomi, SVP, Managing Director of Analytics, shared his expertise on mastering metrics. Let’s explore key insights from his perspective. Audience-Centric Metrics: Historically, marketers relied on superficial metrics like likes and shares.
This chart shows the drugs with the most patents in European Patent Office. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content